100 related articles for article (PubMed ID: 18391401)
1. Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin.
Bandeiras TM; Hillig RC; Matias PM; Eberspaecher U; Fanghänel J; Thomaz M; Miranda S; Crusius K; Pütter V; Amstutz P; Gulotti-Georgieva M; Binz HK; Holz C; Schmitz AA; Lang C; Donner P; Egner U; Carrondo MA; Müller-Tiemann B
Acta Crystallogr D Biol Crystallogr; 2008 Apr; 64(Pt 4):339-53. PubMed ID: 18391401
[TBL] [Abstract][Full Text] [Related]
2. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
Elling RA; Fucini RV; Romanowski MJ
Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):909-18. PubMed ID: 18703838
[TBL] [Abstract][Full Text] [Related]
3. Chaperone-assisted crystallography with DARPins.
Sennhauser G; Grütter MG
Structure; 2008 Oct; 16(10):1443-53. PubMed ID: 18940601
[TBL] [Abstract][Full Text] [Related]
4. Structure of the catalytic domain of human polo-like kinase 1.
Kothe M; Kohls D; Low S; Coli R; Cheng AC; Jacques SL; Johnson TL; Lewis C; Loh C; Nonomiya J; Sheils AL; Verdries KA; Wynn TA; Kuhn C; Ding YH
Biochemistry; 2007 May; 46(20):5960-71. PubMed ID: 17461553
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Johnson EF; Stewart KD; Woods KW; Giranda VL; Luo Y
Biochemistry; 2007 Aug; 46(33):9551-63. PubMed ID: 17655330
[TBL] [Abstract][Full Text] [Related]
6. Discovery of thiophene inhibitors of polo-like kinase.
Emmitte KA; Andrews CW; Badiang JG; Davis-Ward RG; Dickson HD; Drewry DH; Emerson HK; Epperly AH; Hassler DF; Knick VB; Kuntz KW; Lansing TJ; Linn JA; Mook RA; Nailor KE; Salovich JM; Spehar GM; Cheung M
Bioorg Med Chem Lett; 2009 Feb; 19(3):1018-21. PubMed ID: 19097784
[TBL] [Abstract][Full Text] [Related]
7. Stabilizing ionic interactions in a full-consensus ankyrin repeat protein.
Merz T; Wetzel SK; Firbank S; Plückthun A; Grütter MG; Mittl PR
J Mol Biol; 2008 Feb; 376(1):232-40. PubMed ID: 18155045
[TBL] [Abstract][Full Text] [Related]
8. Selectivity-determining residues in Plk1.
Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the SH3 domain of betaPIX in complex with a high affinity peptide from PAK2.
Hoelz A; Janz JM; Lawrie SD; Corwin B; Lee A; Sakmar TP
J Mol Biol; 2006 Apr; 358(2):509-22. PubMed ID: 16527308
[TBL] [Abstract][Full Text] [Related]
10. The extended conformation of the 2.9-Å crystal structure of the three-PASTA domain of a Ser/Thr kinase from the human pathogen Staphylococcus aureus.
Paracuellos P; Ballandras A; Robert X; Kahn R; Hervé M; Mengin-Lecreulx D; Cozzone AJ; Duclos B; Gouet P
J Mol Biol; 2010 Dec; 404(5):847-58. PubMed ID: 20965199
[TBL] [Abstract][Full Text] [Related]
11. DARPin-Based Crystallization Chaperones Exploit Molecular Geometry as a Screening Dimension in Protein Crystallography.
Batyuk A; Wu Y; Honegger A; Heberling MM; Plückthun A
J Mol Biol; 2016 Apr; 428(8):1574-88. PubMed ID: 26975886
[TBL] [Abstract][Full Text] [Related]
12. Structure and function of Polo-like kinases.
Lowery DM; Lim D; Yaffe MB
Oncogene; 2005 Jan; 24(2):248-59. PubMed ID: 15640840
[TBL] [Abstract][Full Text] [Related]
13. The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue.
Nassar N; Horn G; Herrmann C; Scherer A; McCormick F; Wittinghofer A
Nature; 1995 Jun; 375(6532):554-60. PubMed ID: 7791872
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Schöffski P
Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitination and proteasome mediated degradation of polo-like kinase.
Ferris DK; Maloid SC; Li CC
Biochem Biophys Res Commun; 1998 Nov; 252(2):340-4. PubMed ID: 9826531
[TBL] [Abstract][Full Text] [Related]
16. Identifying protein construct variants with increased crystallization propensity--a case study.
Malawski GA; Hillig RC; Monteclaro F; Eberspaecher U; Schmitz AA; Crusius K; Huber M; Egner U; Donner P; Müller-Tiemann B
Protein Sci; 2006 Dec; 15(12):2718-28. PubMed ID: 17132859
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors.
Hanan EJ; Fucini RV; Romanowski MJ; Elling RA; Lew W; Purkey HE; VanderPorten EC; Yang W
Bioorg Med Chem Lett; 2008 Oct; 18(19):5186-9. PubMed ID: 18790636
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Fucini RV; Hanan EJ; Romanowski MJ; Elling RA; Lew W; Barr KJ; Zhu J; Yoburn JC; Liu Y; Fahr BT; Fan J; Lu Y; Pham P; Choong IC; VanderPorten EC; Bui M; Purkey HE; Evanchik MJ; Yang W
Bioorg Med Chem Lett; 2008 Oct; 18(20):5648-52. PubMed ID: 18793847
[TBL] [Abstract][Full Text] [Related]
19. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
Chopra P; Sethi G; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase, a novel marker for cellular proliferation.
Yuan J; Hörlin A; Hock B; Stutte HJ; Rübsamen-Waigmann H; Strebhardt K
Am J Pathol; 1997 Apr; 150(4):1165-72. PubMed ID: 9094972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
